Latest broker call...
Credit Suisse 26/09/2011
Credit Suisse notes the Australian Pharmaceutical Benefits Advisory Committee will meet in November and a review of the Pharmaxis submission for using Bronchitol to treat Cystic Fibrosis is expected.
More important will be the European CHMP decision regarding the company's appeal of a negative vote for Bronchitol in Cystic Fibrosis, with the probability of this appeal difficult to predict in the broker's view. Neutral rating is retained.
Target price is $1.11
crazy price, page-25
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
